Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Hasbro, Inc. · HAS · FY2026 Q2 · Calendar Q3 2026
Hasbro's Q2 2026 confirms that the Wizards of the Coast flywheel is accelerating, not cooling. Magic: The Gathering revenue grew 32% year-over-year, driving the Wizards segment up 27%, while the Marvel Super Heroes set became the fastest Magic release to reach $300 million. Revenue of $1.14 billion beat consensus by 6.6% and EPS of $1.28 exceeded estimates by 10.3%, prompting management to raise full-year guidance to 5-7% revenue growth and 25-26% adjusted operating margin — a meaningful upgrade from Q1's maintained stance. The stock responded with an 8.8% gain on roughly 4x normal volume and continued to drift higher. The key question is whether Magic's momentum and new licensing agreements — particularly the Nintendo Zelda deal — can sustain this pace into 2027, even as the company absorbs a $56 million digital impairment and ramps marketing spend for upcoming video game launches.
Hasbro, Inc., alongside its various subsidiaries, operates as a global leader in the play and entertainment industry. Its Consumer Products segment focuses on the procurement, marketing, and global distribution of toys and games. This division further amplifies its brands by out-licensing trademarks, characters, and intellectual property rights to third parties, enabling the creation and sale of a diverse range of branded consumer goods, such as apparel and toys. Its extensive product catalog encompasses action figures, arts and crafts supplies, fashion dolls and other figurines, playsets, preschool toys, plush items, sports-action blasters and accessories, toy vehicles, and specialty play items, in addition to various traditional games. The company also offers licensed merchandise spanning apparel, publishing, home goods, electronics, and toy products.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Argus Research | Buy | Buy | Maintain | Jul 23, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 22, 2026 |
| DA Davidson | Neutral | Neutral | Maintain | Jul 22, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 16, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 16, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Roth Capital | Buy | Buy | Maintain | Jul 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 10, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jun 9, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 14, 2026 |
| UBS | Buy | Buy | Maintain | Mar 5, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 11, 2026 |
| Roth MKM | Buy | Buy | Maintain | Feb 21, 2025 |
| Stifel | Buy | Buy | Maintain | Jan 3, 2025 |
| MKM Partners | Buy | Buy | Maintain | Jan 13, 2023 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jan 4, 2023 |
| Truist Securities | Hold | Hold | Maintain | Oct 5, 2022 |
| Keybanc | Overweight | Downgrade | Jul 13, 2022 | |
| Consumer Edge Research | Equal Weight | Overweight | Downgrade | Jun 9, 2020 |
| Barclays | Overweight | Overweight | Maintain | May 4, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Apr 30, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Oct 1, 2019 |
| Argus | Hold | Buy | Downgrade | Apr 25, 2019 |
| Monness, Crespi, Hardt | Neutral | Buy | Downgrade | Jul 24, 2018 |
| Monness Crespi Hardt | Neutral | Buy | Downgrade | Jul 24, 2018 |
| B. Riley Securities | Buy | Buy | Maintain | Jul 24, 2018 |
| B. Riley FBR | Buy | Buy | Maintain | Jul 24, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Nov 28, 2016 |
| Piper Sandler | Neutral | Overweight | Downgrade | Nov 28, 2016 |
| Oppenheimer | Perform | Perform | Maintain | Aug 20, 2015 |
| Needham | Hold | Buy | Downgrade | Apr 4, 2014 |
| Sterne Agee | Neutral | Buy | Downgrade | Feb 15, 2012 |
Upside is calculated against the persisted current price $94.12. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Arpine Kocharyan | $120 | $89.3 | +27.5% | Jul 27, 2026 |
| D.A. Davidson | Analyst unavailable | $95 | $88.09 | +0.9% | Jul 22, 2026 |
| Jefferies | Analyst unavailable | $110 | $81.76 | +16.9% | Jul 16, 2026 |
| UBS | Arpine Kocharyan | $110 | $84.72 | +16.9% | Jun 18, 2026 |
| Wells Fargo | Analyst unavailable | $85 | $83.54 | -9.7% | Jun 9, 2026 |
| Wells Fargo | Anthony Bonadio | $92 | $88.6 | -2.3% | May 21, 2026 |
| Morgan Stanley | Analyst unavailable | $123 | $96.73 | +30.7% | May 14, 2026 |
| Morgan Stanley | Megan Alexander Clapp | $122 | $96.56 | +29.6% | Apr 24, 2026 |
| Argus Research | Christine Dooley | $105 | $95.11 | +11.6% | Mar 13, 2026 |
| Morgan Stanley | Analyst unavailable | $119 | $106.35 | +26.4% | Feb 11, 2026 |
| Roth Capital | Analyst unavailable | $120 | $105.25 | +27.5% | Feb 11, 2026 |
| D.A. Davidson | Analyst unavailable | $110 | $104.44 | +16.9% | Feb 11, 2026 |
| Goldman Sachs | Stephen Laszczyk | $114 | $104 | +21.1% | Feb 11, 2026 |
| Roth Capital | Analyst unavailable | $105 | $96.4 | +11.6% | Feb 4, 2026 |
| Morgan Stanley | Analyst unavailable | $103 | $90.47 | +9.4% | Feb 2, 2026 |
| UBS | Analyst unavailable | $99 | $87.06 | +5.2% | Jan 7, 2026 |
| Morgan Stanley | Megan Alexander | $94 | $81.55 | -0.1% | Dec 14, 2025 |
| Morgan Stanley | Analyst unavailable | $87 | $79.25 | -7.6% | Oct 24, 2025 |
| Roth Capital | Eric Handler | $96 | $77.94 | +2.0% | Oct 24, 2025 |
| Goldman Sachs | Michael Ng | $85 | $73.82 | -9.7% | Jun 30, 2025 |
| D.A. Davidson | Keegan Cox | $75 | $65.21 | -20.3% | May 14, 2025 |
| CFRA | Zachary Warring | $90 | $66.1 | -4.4% | Oct 24, 2024 |
| Bank of America Securities | Alexander Perry | $95 | $71.57 | +0.9% | Oct 15, 2024 |
| Bank of America Securities | Jason Haas | $90 | $68.73 | -4.4% | Sep 16, 2024 |
| Morgan Stanley | Megan Alexander | $79 | $62.05 | -16.1% | Jul 26, 2024 |
| CFRA | Zachary Warring | $72 | $61.52 | -23.5% | Jul 25, 2024 |
| Morgan Stanley | Megan Alexander | $77 | $65.03 | -18.2% | Apr 24, 2024 |
| Stifel Nicolaus | Drew Crum | $67 | $55.8 | -28.8% | Apr 15, 2024 |
| CFRA | Zachary Warring | $59 | $55.85 | -37.3% | Apr 4, 2024 |
| Stifel | Drew Crum | $64 | $53.31 | -32.0% | Mar 15, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $80 | $52.06 | -15.0% | Apr 5, 2023 |
| MKM Partners | Analyst unavailable | $80 | $65.36 | -15.0% | Jan 13, 2023 |
| BMO Capital | Analyst unavailable | $66 | $61.95 | -29.9% | Jan 4, 2023 |
| Stifel Nicolaus | Drew Crum | $84 | $68.42 | -10.8% | Oct 5, 2022 |
| BMO Capital | Analyst unavailable | $80 | $81.31 | -15.0% | Jul 21, 2022 |
| Truist Financial | Analyst unavailable | $88 | $80.57 | -6.5% | Jul 20, 2022 |
| Jefferies | Analyst unavailable | $100 | $78.32 | +6.2% | Jul 15, 2022 |
| MKM Partners | Analyst unavailable | $105 | $82.58 | +11.6% | Jul 7, 2022 |
| Jefferies | Stephanie Wissink | $115 | $91.84 | +22.2% | May 3, 2022 |
| D.A. Davidson | Linda Bolton Weiser | $128 | $87.93 | +36.0% | Apr 25, 2022 |
| KeyBanc | Brett Andress | $105 | $88.86 | +11.6% | Apr 20, 2022 |
| Goldman Sachs | Michael Ng | $100 | $87.02 | +6.2% | Apr 19, 2022 |
| Jefferies | Matthew Catton | $120 | $92.29 | +27.5% | Feb 8, 2022 |
| Truist Financial | Michael Swartz | $100 | $93.22 | +6.2% | Oct 27, 2021 |
| Bank of America Securities | Devin Brisco | $110 | $99.22 | +16.9% | Jul 27, 2021 |
Track every rating change on HAS the moment it posts. Free to start.
Start freeFollow HAS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeRevenue growth accelerated from 13% in Q1 to 16% in Q2, with Wizards segment growth rising from 26% to 27%. Guidance moved from maintained to raised, reflecting management's increased confidence. The cyber incident impact was disclosed as approximately $25 million with operations fully restored, an improvement from Q1's $20 million in costs plus $40-60 million in delayed Consumer Products revenue. Cost transformation savings grew from $37 million to $70 million. New developments include a $56 million non-cash digital impairment, the Nintendo Zelda licensing agreement, Marvel Super Heroes' record performance, and an increased share repurchase target of at least $200 million.
Management shifted from maintaining full-year guidance in Q1 to raising it in Q2, now targeting 5-7% revenue growth and 25-26% adjusted operating margin. The upgrade reflects stronger-than-expected Wizards performance and confidence that delayed Consumer Products revenue from the cyber incident is recovering. Cost transformation savings have accelerated from $37 million to $70 million year-to-date.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.